Skip to main content
رجوع
GMED logo

Globus Medical, Inc.

جودة البيانات: 100%
GMED
NYSE Healthcare Medical - Devices
KWD 87.21
▲ KWD 0.95 (1.10%)
القيمة السوقية: 11.80B
نطاق اليوم
KWD 86.84 KWD 88.36
نطاق 52 أسبوعًا
KWD 51.79 KWD 101.40
حجم التداول
551,679
متوسط 50 يوم / 200 يوم
KWD 90.26 / KWD 72.41
الإغلاق السابق
KWD 86.26

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 21.9 0.4
P/B 2.6 2.9
ROE % 12.3 3.8
Net Margin % 18.3 3.9
Rev Growth 5Y % 32.3 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 104.000 +19.3%
Low: KWD 64.000 High: KWD 115.000
مكرر الربحية المستقبلي
19.7
ربحية السهم المستقبلية
KWD 4.423
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
3.2 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 6.995
KWD 6.917 – KWD 7.112
4.2 B 1
FY2029 KWD 6.290
KWD 6.220 – KWD 6.395
4 B 1
FY2028 KWD 5.394
KWD 4.928 – KWD 6.041
3.6 B 3

النقاط الرئيسية

Revenue grew 32.34% annually over 5 years — strong growth
Earnings grew 422.31% over the past year
ROE of 12.29% — decent returns on equity
Net margin of 18.30% shows strong profitability
Debt/Equity of 0.03 — conservative balance sheet
Generating 588.77M in free cash flow

النمو

Revenue Growth (5Y)
32.34%
Revenue (1Y)16.65%
Earnings (1Y)422.31%
FCF Growth (3Y)88.77%

الجودة

Return on Equity
12.29%
ROIC7.67%
Net Margin18.30%
Op. Margin16.33%

الأمان

Debt / Equity
0.03
Current Ratio4.26
Interest Coverage0.00

التقييم

P/E Ratio
21.93
P/B Ratio2.58
EV/EBITDA23.73
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16.65% Revenue Growth (3Y) 36.88%
Earnings Growth (1Y) 422.31% Earnings Growth (3Y) 109.23%
Revenue Growth (5Y) 32.34% Earnings Growth (5Y) 37.80%
Profitability
Revenue (TTM) 2.94B Net Income (TTM) 537.90M
ROE 12.29% ROA 10.14%
Gross Margin 67.41% Operating Margin 16.33%
Net Margin 18.30% Free Cash Flow (TTM) 588.77M
ROIC 7.67% FCF Growth (3Y) 88.77%
Safety
Debt / Equity 0.03 Current Ratio 4.26
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 21.93 P/B Ratio 2.58
P/S Ratio 4.01 PEG Ratio 0.05
EV/EBITDA 23.73 Dividend Yield 0.00%
Market Cap 11.80B Enterprise Value 11.39B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2.94B 2.52B 1.57B 1.02B 958.10M
Net Income 537.90M 102.98M 122.87M 190.17M 149.19M
EPS (Diluted) 3.92 0.75 1.07 1.85 1.44
Gross Profit 1.98B 1.48B 1.02B 759.12M 718.88M
Operating Income 479.80M 165.99M 133.14M 227.95M 171.95M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 5.30B 5.25B 5.09B 2.08B 1.96B
Total Liabilities 729.51M 1.07B 1.09B 229.75M 215.88M
Shareholders' Equity 4.57B 4.18B 4.00B 1.85B 1.74B
Total Debt 118.66M 537.19M 520.40M 6.01M 0.0
Cash & Equivalents 526.16M 784.44M 467.29M 150.47M 193.07M
Current Assets 2.13B 2.18B 1.92B 983.34M 864.52M
Current Liabilities 498.50M 855.91M 392.35M 159.20M 140.16M

درجات الاستراتيجيات

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
#981 of 1024
18
#33 of 326
73

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026
دخل Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026